J Ouyang1, X Gou, Y Ma, Q Huang, T Jiang. 1. Department of Laboratory Medicine, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China.
Abstract
INTRODUCTION: Previous studies have indicated that a deletion on the short arm of chromosome 1 negatively predicts survival in patients with multiple myeloma (MM). Due to the small sample size in each study, we performed this meta-analysis to comprehensively investigate the association between the 1p deletion and survival in patients with MM. METHODS: A literature search was conducted in both foreign and Chinese databases, including SinoMed, CNKI, Wanfang, PubMed, EMBASE, and Scopus. Hazard ratios (HR) with 95% confidence intervals (CI) for overall survival (OS) and progression-free survival (PFS) in 11 eligible articles were extracted or calculated to analyze the pooled HR, which was estimated by fixed-effect or random-effect models based on the heterogeneity between included articles. A subgroup analysis and a meta-regression were conducted, and Galbraith plots were generated to examine any possible heterogeneity. RESULTS: The HRs for OS were available in nine articles, whereas five articles discussed HRs for PFS. The HR with 95%CI was 1.989 (95%CI 1.522-2.600, P = 0.017, I(2) = 57.1%) when comparing the OS of patients with 1p deletion with the OS of those without this deletion. For PFS, 1p deletion still predicted a poor prognosis (HR 2.11, 95%CI 1.54-2.88, P = 0.292, I(2) = 19.3%). Moreover, the subgroup analysis suggested that either the deleted gene on 1p or techniques for detecting chromosome abnormalities contributed to the heterogeneity, which was partially consistent with the results derived from a meta-regression analysis and the Galbraith plot method. CONCLUSION: Our meta-analysis provides globally quantifiable confirmation of the adverse prognostic role of 1p deletion in OS and PFS for patients with MM.
INTRODUCTION: Previous studies have indicated that a deletion on the short arm of chromosome 1 negatively predicts survival in patients with multiple myeloma (MM). Due to the small sample size in each study, we performed this meta-analysis to comprehensively investigate the association between the 1p deletion and survival in patients with MM. METHODS: A literature search was conducted in both foreign and Chinese databases, including SinoMed, CNKI, Wanfang, PubMed, EMBASE, and Scopus. Hazard ratios (HR) with 95% confidence intervals (CI) for overall survival (OS) and progression-free survival (PFS) in 11 eligible articles were extracted or calculated to analyze the pooled HR, which was estimated by fixed-effect or random-effect models based on the heterogeneity between included articles. A subgroup analysis and a meta-regression were conducted, and Galbraith plots were generated to examine any possible heterogeneity. RESULTS: The HRs for OS were available in nine articles, whereas five articles discussed HRs for PFS. The HR with 95%CI was 1.989 (95%CI 1.522-2.600, P = 0.017, I(2) = 57.1%) when comparing the OS of patients with 1p deletion with the OS of those without this deletion. For PFS, 1p deletion still predicted a poor prognosis (HR 2.11, 95%CI 1.54-2.88, P = 0.292, I(2) = 19.3%). Moreover, the subgroup analysis suggested that either the deleted gene on 1p or techniques for detecting chromosome abnormalities contributed to the heterogeneity, which was partially consistent with the results derived from a meta-regression analysis and the Galbraith plot method. CONCLUSION: Our meta-analysis provides globally quantifiable confirmation of the adverse prognostic role of 1p deletion in OS and PFS for patients with MM.
Authors: Adrian A Carballo-Zarate; L Jeffrey Medeiros; Lianghua Fang; Jatin J Shah; Donna M Weber; Sheeba K Thomas; Elisabet E Manasanch; Suyang Hao; Qi Shen; Robert Z Orlowski; Pei Lin; Xinyan Lu Journal: Mod Pathol Date: 2017-03-10 Impact factor: 7.842
Authors: Martin Granzow; Ute Hegenbart; Katrin Hinderhofer; Dirk Hose; Anja Seckinger; Tilmann Bochtler; Kari Hemminki; Hartmut Goldschmidt; Stefan O Schönland; Anna Jauch Journal: Haematologica Date: 2017-03-24 Impact factor: 9.941